ARTICLE | Clinical News
LJPC-401: Phase I started
November 9, 2015 8:00 AM UTC
La Jolla began an open-label, dose-escalation Phase I trial to evaluate LJPC-401 in patients at risk of iron overload due to conditions such as hereditary hemochromatosis, beta thalassemia and sickle ...